Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nCTLs and alphaDC1 vaccine in primary ovarian cancer
NCT03735589Phase 2Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of autologous natural killer cell-like CTLs and alpha-type-1-polarized dendritic cell vaccine in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Roswell Park Comprehensive Cancer Center. Planned start Dec 2023; status: withdrawn.
02
Drugs
autologous natural killer cell-like CTLsalpha-type-1-polarized dendritic cell vaccine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03735589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03735589.